Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Argentina Expands Access To Meds With Public Production

Executive Summary

Argentina is pushing forward with plans to expand access to medicines by driving public production.

You may also be interested in...



Could Argentina give you bang for your buck?

High inflation, a drop in the price of its commodities and restrictions on imports have not made for a good economic environment in Argentina and have proved a turnoff for investors. But a general election is around the corner and there are hopes that a new administration may set things right. So with change blowing in the wind, companies with flagging pipelines should consider what Argentina has to offer, not least a rich R&D community that helped create the world's first ever cancer vaccine against non-small cell lung cancer, and a vibrant local industry open to partnerships .

Brazil to produce its own infliximab

Brazil is to manufacture its own version of Janssen's monoclonal antibody Remicade (infliximab), thanks to a technology transfer deal with Janssen worth R$206mn ($80mn), says the health ministry.

Improve Access to RWD In Asia To Make RWE Viable

Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel